Newsroom
Sorted by: Latest
-
Intellicheck Inaugural Identity Fraud Threat Report Exposes Widespread Fraud Risks Threatening Massive Losses Across Industries
MELVILLE, N.Y.--(BUSINESS WIRE)--Intellicheck, Inc. (Nasdaq: IDN), an industry-leading identity company delivering proprietary on-demand digital and physical identity validation solutions, today announced the release of its inaugural 2026 Intellicheck North America Identity Verification Threat Report. The report provides a comprehensive, data-driven analysis of how the identity fraud landscape is evolving across financial services, retail, and other major industries. It draws on proprietary, an...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Europe Infrastructure UCITS ETF 17.02.2026 FTEI.LN IE000TIZ5AP4 50,002.00 EUR 1,034,539.66 20.690 ...
-
Magnus Medical Moves to Protect Intellectual Property Behind Breakthrough SAINT Accelerated Depression Therapy
BURLINGAME, Calif.--(BUSINESS WIRE)--Magnus Medical sends cease-and-desist letters to protect SAINT, an FDA-cleared breakthrough in accelerated, personalized depression treatment....
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Nuclear Power UCITS ETF 17.02.2026 RCTR.LN IE000J5PESP7 50,002.00 USD 1,001,039.24 20.020 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - December 17.02.2026 MDEC.LN IE0007FIJUO5 50,002.00 USD 1,374,217.59 27.483 ...
-
FDA Approval Granted for Commercial Manufacturing at Rezon Bio's Warsaw-Duchnice Facility
WARSAW, Poland--(BUSINESS WIRE)--Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio’s global manufacturing network and reflects the company’s focus on building robust, compliant, and reliable capabilities to support biologic therapies for patients worldwide. The FDA approval of the Warsaw...
-
Liberty Global Reports Q4 2025 Results
DENVER, Colorado--(BUSINESS WIRE)--Liberty Global Ltd. announces its Q4 2025 financial results. CEO Mike Fries stated, “In the fourth quarter, we continued to execute our plans to both drive commercial momentum in our telecom operations and unlock value for shareholders. Liberty Telecom: We delivered all full-year guidance metrics at VMO2, VodafoneZiggo and Telenet, reflecting growing commercial progress despite challenging competitive environments. VMO2 delivered a sequential improvement in br...
-
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The acquisition brings Faeth’s lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, into...
-
Palogic Value Fund Withdraws Nominees and Shareholder Proposal at Pebblebrook Hotel Trust
DALLAS--(BUSINESS WIRE)--Palogic Value Fund, LP and Palogic Value Management, LP (collectively, “Palogic,” “we” or “our”) issued the following letter on February 17, 2026, to the Board of Trustees (the “Board”) of Pebblebrook Hotel Trust (“Pebblebrook,” or the “Company”) (NYSE: PEB). February 17, 2026 Pebblebrook Hotel Trust c/o Corporate Secretary 4747 Bethesda Avenue, Suite 1100 Bethesda, Maryland 20814 Dear Members of the Board: Palogic is highly encouraged by the steps Pebblebrook has recen...
-
Fraser Reports Record Start to 2026 With 12 Superyacht Sales in 12 Days
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Fraser Yachts (“Fraser”), a leading global superyacht brokerage and services company and a wholly owned subsidiary of MarineMax, Inc. (NYSE: HZO) (“MarineMax”), today announced a strong start to 2026, completing 12 superyacht sales in just 12 days during January. The transactions included a balanced mix of brokerage and new‑build activity involving some of the industry’s most established shipyards, including Lürssen, Feadship, Abeking & Rasmussen, and...